Prof. Mark Cook (University of Melbourne, Australia) stated there is a clear need for a long-term recording system in patients with epilepsy. “These patients are often unaware of their seizures, which may both complicate diagnosis and optimisation of treatment.” Potentially, it could be used for safety alerts and seizure forecasting. They could have a role in clinical trials as well. So far, such systems have been relatively invasive. Ideally, the device would be inserted as a day procedure and involve an unobtrusive external unit such as a smartphone to store and process data. Prof. Cook's group developed such a minimally invasive system themselves, the Minder system, a sub-scalp device. Four electrode contacts are deployed in a coronal plane posterior to the vertex, providing 2 channels of data. EEG data is continuously captured and transferred to a smartphone, from where it is accessible remotely by internet.
Prof. Cook presented preliminary results of a registered clinical trial of the Minder system in 9 patients with refractory epilepsy with at least 1 seizure weekly [1]. Recordings were compared to a 1-week in-patient video-EEG monitoring session for 4 of these subjects. EEG recordings from both systems were reviewed blindly by 2 neurologists. The procedures were uncomplicated and well tolerated, without any significant complications and with excellent compliance. High-quality EEG data was captured continuously. The monitoring system captured all 31 events identified during the video-EEG period from the 4 subjects. Two events were initially identified on the system alone. Of the 20 patient-reported events, 12 were not associated with clinical or EEG changes on either system. Prof. Cook added that seizure forecasting is feasible using this system.
- Cook M, et al. Preliminary experience using a minimally invasive sub-scalp device for ultra-long term seizure monitoring. EPR-311, EAN 2021 Virtual Congress, 19–22 June.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Long-term effectiveness of ANT-DBS in epilepsy confirmed Next Article
First evidence of brainstem involvement in COVID-19 »
« Long-term effectiveness of ANT-DBS in epilepsy confirmed Next Article
First evidence of brainstem involvement in COVID-19 »
Table of Contents: EAN 2021
Featured articles
Letter from the Editor
COVID-19
First evidence of brainstem involvement in COVID-19
Cognitive/behavioural alterations persistent after COVID-19
Neural base of persistent hyposmia after COVID-19
Neurological symptoms and complications of COVID-19 affect outcomes
Cerebrovascular Disease
Intracerebral haemorrhage only slightly increases mortality in COVID-19 patients
Stroke with covert brain infarction indicates high vascular risk
Expanding precision medicine to stroke care
Dexamethasone not indicated for chronic subdural haematoma
Cognitive Impairment and Dementia
Severe outcomes of COVID-19 in patients with dementia
Promising diagnostic accuracy of plasma GFAP
Sex modulates effect of cognitive reserve on subjective cognitive decline
Hypersensitivity to uncertainty in subjective cognitive decline
Epilepsy
Minimally invasive device to detect focal seizure activity
‘Mozart effect’ in epilepsy: why Mozart tops Haydn
Migraine and Headache
Factors associated with decreased migraine attack risk
Pregnant migraine patients at higher risk of complications
Occipital nerve stimulation in drug-resistant cluster headache
Rhythmicity in primary headache disorders
Multiple Sclerosis and NMOSD
Typing behaviour to remotely monitor clinical MS status
Alemtuzumab in treatment-naïve patients with aggressive MS
No higher early MS relapse frequency after stopping ponesimod
Good long-term safety and efficacy of inebilizumab in NMOSD
Neuromuscular Disorders
Inability to recognise disgust as first cognitive symptom of ALS
Pathogenic T-cell signature identified in myasthenia gravis
Parkinson’s Disease
Levodopa-carbidopa intestinal gel in patients with advanced PD
New Frontier – Navigated Transcranial Ultrasound
Exploring the possibilities
Related Articles
August 18, 2021
‘Mozart effect’ in epilepsy: why Mozart tops Haydn
August 18, 2021
Effect of prasinezumab on motor features in early PD
August 18, 2021
First evidence of brainstem involvement in COVID-19
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com